ASH 2022 | The impact of IDH mutations on the outcomes of patients with AML & inhibitors under investigation
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, outlines the impact of IDH mutations on treatment outcomes of patients with acute myeloid leukemia (AML). Dr Röllig describes how, with intensive chemotherapy, IDH mutation confers an intermediate risk, but when hypomethylating agents (HMAs) or cytarabine are combined with venetoclax, these mutations confer a favorable prognosis. Dr Röllig also discusses IDH inhibitors currently under clinical investigation, including ivosidenib and enasidenib. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Consultancy, Honoraria; Amgen: Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Servier: Consultancy; Jazz: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria.
